Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Assets (2016 - 2026)

Anika Therapeutics has reported Current Assets over the past 17 years, most recently at $93.6 million for Q1 2026.

  • Quarterly Current Assets fell 8.73% to $93.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $93.6 million through Mar 2026, down 8.73% year-over-year, with the annual reading at $103.4 million for FY2025, 9.06% down from the prior year.
  • Current Assets was $93.6 million for Q1 2026 at Anika Therapeutics, down from $103.4 million in the prior quarter.
  • Over five years, Current Assets peaked at $169.5 million in Q4 2022 and troughed at $93.6 million in Q1 2026.
  • The 5-year median for Current Assets is $155.0 million (2024), against an average of $139.2 million.
  • Year-over-year, Current Assets grew 1.84% in 2024 and then plummeted 35.92% in 2025.
  • A 5-year view of Current Assets shows it stood at $169.5 million in 2022, then fell by 3.68% to $163.3 million in 2023, then tumbled by 30.41% to $113.7 million in 2024, then dropped by 9.06% to $103.4 million in 2025, then decreased by 9.48% to $93.6 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Current Assets are $93.6 million (Q1 2026), $103.4 million (Q4 2025), and $101.6 million (Q3 2025).